MYD88 and neoplasm: In conclusion, our current study defines that downregulation of MyD88 in murine melanoma B16 cells suppresses its angiogenic potential, culminating in significantly impaired subcutaneous tumor growth, associated with a dysregulation of the expression of genes involved in inflammation and angiogenesis.